TYK2 and psoriasis: Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient‐Reported Outcomes in a Randomized Trial